American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

American Head & Neck Society | AHNS


The mission of the AHNS is to advance Education, Research, and Quality of Care for the head and neck oncology patient.

  • About
    • Mission Statement and Purpose
    • Divisions & Services of the Society
      • Education
        • Scientific Program/Resident Courses
        • Surgical Videos
        • Journal Club
        • Journals
        • Global Outreach
        • Awards
          • Margaret F. Butler Award
      • Diversity, Equity and Inclusion Division
      • Patient Care
        • Cancer Survivorship
          • Patient Education on Post-Treatment Care
          • Interviews with Cancer Survivors
        • Cancer Prevention
          • SLIDE DECK: HPV-Related Oropharyngeal Cancer
        • Guidelines/Position Statements
        • Find-A-Physician
      • Research
        • Grant Information
        • Clinical Trial
        • Tissue Banks
      • Administrative Divison
        • Development Service Process for Evaluating Projects Requiring Funding
    • Leadership
    • History
      • Society Background
      • AHNS History Interviews
      • Past Presidents
      • In Memory
    • AHNS Newsletter
    • Professionalism & Ethics
    • AHNS Policies and Procedures (P&P) Manual
    • AHNS Foundation
    • AHNS Bylaws
    • AHNS Staff
    • AHNS News and Announcements
    • COVID-19 Bulletin Board
  • Heads Up!
  • Post a Job
  • Meetings
    • AHNS Virtual Education Series
      • TORS Webinar Series
    • AHNS Meetings Info
    • AHNS Call For Abstracts
    • AHNS Call For Late Breaking Abstracts
    • Exhibitor and Support Opportunities
    • Past Meetings
    • Related Meetings
  • For Patients
  • For Trainees
    • Accredited Fellowships
      • Fellowship Match
      • Directory of Fellowships
      • Fellowship Curriculum
      • Certificate of Completion Request
      • Fellowship Graduates
      • For Program Directors
      • For Current AHNS Fellows
    • AHNS Surgical Videos
    • Fellows’ Virtual Tumor Boards
    • Cutaneous Cancer
  • Sections
    • Endocrine Surgery
    • Skull Base Surgery Section
    • Reconstructive Head & Neck Surgery
    • Mucosal Malignancy Section
      • Mucosal Malignancy Section Patient Information
    • Salivary Gland
    • Cutaneous Cancer
  • Member Central
    • Join AHNS
    • Find-A-Physician
    • Mailing List Order
  • Log In
  • Donate

AHNS 2010 Presentations

[tabs] [tab title=”Wednesday 4/28/2010“]
  • INTRODUCTION OF GUESTS OF HONOR: John A. Ridge, MD, PhD & Bhuvanesh Singh, MD, PhD
  • AHNS Annual Meeting 2010 Las Vegas, Nevada – Program

Scientific Program

PLENARY SESSION #1: CLINICAL
Moderators: Jeffrey Scott Magnuson, MD, Andy Trotti, MD and Bevan Yueh, MD

  • S001: QUALITY AND PERFORMANCE INDICATORS FOR AN ACADEMIC HEAD AND NECK SURGICAL ONCOLOGY DEPARTMENT: Randal S Weber, MD
  • S002: TRANSORAL ROBOTIC SURGERY (TORS): A MULTICENTER STUDY TO ASSESS SAFETY,
    FEASIBILITY AND EFFICACY. Gregory S Weinstein MD FACS, Professor and Vice Chairman
  • S003: EVALUATION OF GRADE 3/4 MUCOSITIS AND DYSPHAGIA FOR THREE DIFFERENT
    RADIOTHERAPY REGIMENS, WITH AND WITHOUT CETUXIMAB, IN LOCOREGIONALLY ADVANCED HEAD AND NECK CANCER. J A Bonner, MD
  • AHNS Commentary on Cetuximab Trial: Discussant: Andy Trotti, MD

JOHN J. CONLEY LECTURE

  • “Cancer Clinical Trials – The Engine for Progress” Robert L. Comis, MD

CLINICAL POSTER DISCUSSION

  • POSTER DISCUSSION: Moderator: Gady Har-El, MD

SCIENTIFIC SESSION #1
Moderators: Elizabeth A. Blair, MD, Snehal Patel, MD and Erich M. Sturgis, MD

  • S004: FIRST REPORT OF VALIDATION OF THE SYDNEY SWALLOW QUESTIONNAIRE (SSQ) IN A HEAD AND NECK CANCER POPULATION: Raghav Dwivedi, MRCS DOHNS MS
  • S005: HEAD AND NECK CANCER PATIENTS REFERRED TO A TERTIARY CENTER AFTER PRIOR TREATMENT: COMPLIANCE WITH OR DEVIATION FROM NATIONAL COMPREHENSIVE CANCER NETWORK TREATMENT GUIDELINES. Carol M Lewis, MD MPH
  • S006: DISPARITIES IN HEAD AND NECK CANCER TREATMENT BASED ON AGE. Alexander Langerman, MDS
  • 007: SALVAGE SURGERY AFTER ORGAN PRESERVATION REGIMENS: Rachel M BrockS
  • 008: IMPACT OF TIME INTERVAL FROM BIOPSY TO START OF TREATMENT: Gregory J Kubicek, MD
  • S009: MANAGEMENT OF EARLY T-STAGE TONSILLAR CARCINOMAS – RETROSPECTIVE COMPARISON
    OF RADICAL TONSILLECTOMY VERSUS RADIATION FROM A SINGLE INSTITUTION. Eric D Lamarre, MD

PANEL: OPTIMAL ADJUVANT TREATMENT FOR HIGH-RISK ORAL CANCER
Panel Moderator: Bhuvanesh Singh, MD, PhD

  • Overview of Post-Operative Adjuvant Therapy for Head and Neck Cancer: Arlene A. Forastiere, MD
  • EORTC 22931/ RTOG 9501: Cases

AHNS BUSINESS MEETING FOR MEMBERS

  • Treasurers Report To Membership April 2010 Las Vegas NV: Mark K Wax MD

COMBINED OTOLARYNGOLOGY SPRING MEETING 2010

  • MicroRNA-21 Specific Targets in Head and Neck Squamous Cell Carcinoma: Wojciech K. Mydlarz, MD

SCIENTIFIC SESSION #2
Moderators: Claudio R. Cernea, MD, David Kutler, MD and Kepal N. Patel, MD

  • S010: POSTOPERATIVE RADIOTHERAPY IN MUCOSAL MELANOMA OF THE HEAD AND NECK. A FRENCH
  • GETTEC MULTICENTRIC STUDY. Adil BENLYAZID, MD
  • S011: COMPARTMENTAL SURGERY IN TONGUE TUMORS: LONG TERM ONCOLOGIC EVALUATION OF A NEW SURGICAL TECHNIQUE VS. CONVENTIONAL DEMOLITIVE TONGUE SURGERY. A FOURTEEN-YEAR CLINICAL EXPERIENCE: Luca Calabrese, MD
  • S012: TPF INDUCTION THERAPY WITH RADIOIMMUNOCHEMOTHERAPY FOR THE TREATMENT OF HEAD & NECK CANCER: Wolf Oliver Jordan
  • S013: TARGETING CK2 BY SMALL MOLECULE INHIBITOR DMAT MODULATES NF-KAPPAB AND TP53 SIGNALING, SURVIVAL AND MIGRATION IN HEAD AND NECK CANCER: Vishnu R Kannabiran, BS
  • S015: AKT PHOSPHORYLATION AS A MARKER OF RESISTANCE TO ZD6474 (VANDETANIB) IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: Genevieve A Andrews

JATIN P. SHAH SYMPOSIUM ON CLINICAL CONTROVERSIES IN HEAD AND NECK SURGERY
UPDATE OF CLINICAL TRIALS IN HEAD & NECK ONCOLOGY
Panel Moderator: Gregory T. Wolf, MD

  • Update of RTOG 91-11: Arlene A. Forastiere, MD
  • European Organ Preservation Trials: Jan B. Vermorken, MD, PhD

SCIENTIFIC SESSION #3 – RECONSTRUCTION
Moderators: Gerry F. Funk, MD, Neal D. Futran, MD, DMD and Derrick Lin, MD

  • S016: A BLOOD TRANSFUSION PREDICTION MODEL IN PATIENTS UNDERGOING MAJOR HEAD & NECK SURGERY INVOLVING FREE FLAP RECONSTRUCTION: Manish D Shah, MD MPhil FRCSC
  • S017: A CLASSIFICATION SYSTEM FOR RECONSTRUCTION OF VERTICAL HEMIPHARYNGOLARYNGECTOMY FOR HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA: Min-Sik Kim, MD PhD,
  • S018: THE NATURE AND EXTENT OF BODY IMAGE CONCERNS AMONG SURGICALLY TREATED PATIENTS WITH HEAD AND NECK CANCER: NEW FINDINGS TO PROMOTE IMPROVED PSYCHOSOCIAL CARE: Michelle C Fingeret, PhD
  • S019: SUBMENTAL FLAP VERSUS RADIAL FOREARM FLAP FOR ORAL CAVITY RECONSTRUCTION: COMPARISON OF OUTCOMES: Urjeet A Patel, MD

PANEL: NEW HORIZONS IN HEAD AND NECK RECONSTRUCTION
Panel Moderator: Joseph J. Disa, MD
Panelists: Matthew M. Hanasono, MD, Eben L. Rosenthal, MD and Mark K. Wax, MD

  • Head and Neck Reconstruction Panel

SCIENTIFIC SESSION #4
Moderators: Sandeep Samant, MS, Richard V. Smith, MD and Richard J. Wong, MD

  • S020: LOCAL RESPONSE TO CHEMORADIOTHERAPY FOR T4 LARYNGEAL/HYPOPHARYNGEAL CARCINOMA WITH CARTILAGE INVASION: Lori K Howell, MD
  • S021: DETERMINANTS OF LONG-TERM SPEECH AND SWALLOWING OUTCOMES FOLLOWING CHEMORADIOTHERAPY FOR LOCOREGIONALLY ADVANCED HEAD AND NECK CANCER: K W Mouw, PhD
  • S022: RESIDUAL DISEASE IN POST-CHEMORADIOTHERAPY NECK DISSECTIONS FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: DOES IT AFFECT PROGNOSIS? Hilliary White, MD
  • S023: RETROSPECTIVE ANALYSIS OF MINOR SALIVARY GLAND CARCINOMAS OF THE OROPHARYNX AND FACTORS PREDICTIVE OF OUTCOME: N Gopalakrishna Iyer, MD PhD
  • S024: THE INCIDENCE AND OUTCOME OF HEAD AND NECK SQUAMOUS CELL CARCINOMA PATIENTS WITH SUSPICIOUS PULMONARY FINDINGS ON PET/CT: Bradley A Schiff, MD
  • S025: INDUCTION CHEMOTHERAPY FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUSES: Ehab Y Hanna, MD
[/tab] [tab title=”Thursday 4/29/2010“]

Scientific Program

PLENARY SESSION #2: BASIC SCIENCE
Moderators: Carol R. Bradford, MD, Joseph A. Califano, MD, Robert L. Ferris, MD, PhD and James Rocco, MD, PhD

  • S026: CD40 IS REQUIRED FOR AN IMMUNE MEDIATED CLEARANCE OF HPV POSITIVE HEAD AND NECK CANCER. William C Spanos, MD
  • S027: VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) IS IMPORTANT IN THE DEVELOPMENT AND METASTASIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA: Rachel L Chard, BA
  • S028: SIGNIFICANCE OF CIRCULATING TUMOR CELLS IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. Kris R Jatana, MD
  • S029: ENHANCED INVASIVE AND METASTATIC POTENTIAL OF CANCER STEM CELLS IN HEAD & NECK SQUAMOUS CELL CARCINOMA. Samantha J Davis, BS

BASIC SCIENCE POSTER DISCUSSION
Moderators: Stephen Y. Lai, MD, PhD

HAYES MARTIN LECTURE “Pathogenetic Stratification of Salivary Gland Malignancies: Promise and Potential”
Adel El-Naggar, MD, PhD, Professor of Pathology and Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Texas; Editor-in-Chief, Head and Neck Oncology

AHNS AWARDS CEREMONY
Presented by: Cherie-Ann O. Nathan, MD and Marilene B. Wang, MD

INTRODUCTION OF THE AHNS PRESIDENT
Introduction by David W. Eisele, MD, AHNS President-Elect

AHNS PRESIDENTIAL ADDRESS AND PRESIDENTIAL HONORS
“We Show Pictures, They Show Curves”

John A. Ridge, MD, PhD, Chief of Head & Neck Surgery, Fox Chase Cancer Center, Philadelphia, PA

SCIENTIFIC SESSION #5
Moderators: Michael Kupferman, MD, Ellie Maghami, MD, Jorge Pinho, MD and David L. Schwartz, MD

  • S030: RETROSPECTIVE ANALYSIS OF OUTCOME IN PATIENTS WITH ORAL PREMALIGNANT LESIONS: THE RISK FOR ORAL CANCER DEVELOPMENT. Vanda M Stepanek, MD PhD
  • S031: FLUORESCENT SPECTROSCOPY FOR NON-INVASIVE EARLY DIAGNOSIS OF ORAL MUCOSAL MALIGNANT AND POTENTIAL MALIGNANT LESIONS. Pankaj Chaturvedi, FACS FAIS FICS MNAMS
  • S032: ORAL SQUAMOUS CELL CARCINOMA: PREDICTING PROGNOSIS FOLLOWING RECURRENCE.
    Ardalan Ebrahimi, Dr
  • S033: TARGETING A TREATMENT-RESISTANT, MESENCHYMAL-LIKE SUBPOPULATION WITHIN HEAD
    AND NECK SQUAMOUS CELL CARCINOMAS. Devraj Basu, MD PhD
  • S034: INTRAVASCULAR HUMAN SALIVARY CELL DELIVERY TO TREAT SALIVARY CELL LOSS IN A
    RODENT MODEL. Millie Surati, MD
  • S035: SENSITIZATION OF HEAD AND NECK CANCER TO CISPLATIN THROUGH THE INHIBITION OF STAT3. Waleed M Abuzeid, MD

SCIENTIFIC SESSION #6
Moderators: Terry A. Day, MD, David Goldenberg, MD and Christine G. Gourin, MD

  • S036: DECISION MAKING FOR THE EXTENT OF THYROIDECTOMY IN PATIENTS WITH ATYPICAL CYTOLOGY. Manish D Shah, MD MPhil FRCSC
  • S037: SURGICAL PRACTICE PATTERNS IN THE MANAGEMENT OF PAPILLARY THYROID MICROCARCINOMA. Arthur W Wu, MD
  • S038: VOLUME-BASED TRENDS IN THYROID SURGERY. Christine G Gourin, MD
  • S039: PROPHYLACTIC CENTRAL LYMPH NODE DISSECTION FOR CLINICALLY NODE-NEGATIVE PAPILLARY THYROID MICROCARCINOMA: ITS IMPACT ON POSTOPERATIVE THYROGLOBULIN LEVEL, RECURRENCES AND COMPLICATIONS. Yoon Kyoung So, MD
  • S040: ROUTINE PARATHYROID LOCALIZATION WITH 4-D COMPUTED TOMOGRAPHY/ULTRASOUND IN PATIENTS WITH HYPERPARATHYROIDISM: Rachel A Moquete, BA
  • S041: INTRAOPERATIVE PARATHYROID HORMONE MONITORING IN PARATHYROIDECTOMY; IS IT MANDATORY? Aviram Mizrachi, MD

PANEL: ROLE OF SURGERY IN LABORATORY THYROID CANCER – SUPPORTED BY CLINICAL DATA?

Panel Moderator: Ashok R. Shaha, MD
Panelists: Quan-Yang Duh, MD, Bryan McIver, MBChB, PhD,
Christopher R. McHenry, MD and Lisa A. Orloff, MD

NCCN GUIDELINES DISCUSSION PLATINUM ROOM
Panel Moderator: David G. Pfister, MD “NCCN Guidelines Development Process”

SCIENTIFIC SESSION #7
Moderators: Floyd “Chris” Holsinger, MD, Cherie-Ann O. Nathan, MD and Theodoros N. Teknos, MD

  • S042: INCREASED TOLL-LIKE RECEPTOR EXPRESSION AND ACTIVITY IN REGULATORY T CELLS IN PATIENTS WITH HEAD AND NECK CANCER: Christoph Bergmann, MD PhD
  • S043: CELLULAR IMMUNITY CORRELATES WIHT HUMAN PAPILLOMA VIRUS-16 (HPV-16) STATUS AND OUTCOME IN PATIENTS WITH ADVANCED OROPHARYNGEAL CANCER: Derrick Wansom, BA
  • S044: FAS AND FAS LIGAND POLYMORPHISMS AND RISK OF SECOND PRIMARY MALIGNANCY IN PATIENTS WITH INDEX SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. Mark E Zafereo, MD
  • S045: TRANSORAL SURGERY USING ROBOTIC SURGICAL SYSTEM FOR HYPOPHARYNGEAL CARCINOMAS: Se-Heon Kim, MD
  • S047: TRANSORAL ROBOTIC SURGERY FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA: 1 AND 2-YEAR SURVIVAL ANALYSIS: Hilliary N White, MD

FELLOWSHIP INFORMATION SESSION
Jay Boyle, Memorial Sloan-Kettering Cancer Center
Carol Bradford, University of Michigan

[/tab] [/tabs] [tabs][tab title=”Saturday“]

Instructional Courses

  • HNSCC Cases for AHNS – 3 Cases Presentation
  • SIERRA B: Systemic Therapy in SCCHN
  • SIERRA B: The Role of Systemic Therapy in Locally Advanced Squamous Cell Carcinoma of the Head & Neck
  • SIERRA B: Quality of Head & Neck Cancer Care: How Do We Improve?
  • SIERRA H: Electronic Medical Record Systems in a Head & Neck Oncologic Practice
  • SIERRA H: Screening and Early Diagnosis of Oral Cancer
  • SIERRA H: What’s New in Padiotherapy for Head & Neck Cncer?
  • SIERRA I: IRB/GRANTS – Institutional Review Board 101
  • SIERRA I: Decision making in the Management of the Mandible in Oral Cancer
  • SIERRA I: Nuts and Bolts of Tissue Banking
  • SIERRA I: Quality of Life, Symptom Control and Functional Outcomes
  • SIERRA I: Tumor Board: Oral Cavity “The Role of Sentinel Node Biopsy”
  • SIERRA I: IRB/GRANTS – Get Your Grant Funded
  • SIERRA I: The Abstrusity of QOL
  • NOB HILL A: Multidisciplinary Head & Neck Cancer Care in the Community
  • NOB HILL A: Surgical Options for Distant Metastases
  • NOB HILL A: Multidisciplinary Management of Head & Neck Cancer Care in the Community Setting
  • YERBA SALON 10-11: Linear Stapler in Total Laryngectomy
  • YERBA SALON 10-11: Mini-course on Surgical Technique for Larynx
  • YERBA SALON 10-11: Introduction to Oncogenomics/Proteomics 101
  • YERBA SALON 10-11: Post Operative Radiotherapy for Head & Neck Tumors
  • YERBA SALON 10-11: Minimally Invasive Thyroid. Videoassisted Thyroidectomy
  • YERBA SALON 10-11: Videoassisted Thyroidectomy: Lessons After 2 Years
  • YERBA SALON 10-11: Robotics Neck Surgery: a Systematic Approach to Implementing a New Surgical Technique
  • YERBA SALON 10-11: Adjuvant Radiation and Chemotherapy in the Treatment of Squamous Cell Carcinoma of the Head & Neck
  • YERBA SALON 10-11: Transoral Robotic Surgery (TORS) Program – From the Bench to the Bedside
  • YERBA SALON 12-13: Surgical Technique on Salivary Glands
  • YERBA SALON 12-13: Speech and Swallowing Rehabilitation
  • YERBA SALON 12-13: Surgical Eintervention for Dysphagia and Aspiration
  • YERBA SALON 12-13: Damage Control
  • YERBA SALON 12-13: Instructional Session: Salivary Gland Surgery
  • YERBA SALON 12-13: Sonographic Evaluation of Lymph Nodes with Head & Neck Cancer
  • YERBA SALON 14: The Search for Cancer Stem Cell in Head & Neck Squamous Cell Carcinoma
  • YERBA SALON 14: Combined Therapy for Squamous Cancer of the Oropharyrnx
  • YERBA SALON 14: Combined Therapy for Oropharyrnx Cancer
  • YERBA SALON 14: Target Therapy 101
  • YERBA SALON 15: National Reimbursement Scene for Physicians
  • YERBA SALON 15: Stereolithographic Modeling for Mandibular Reconstruction
  • YERBA SALON 15: Reimbursement in Head &Neck Oncologic Surgery
  • YERBA SALON 15: Management of the Neck in the Treatment of Oropharyngeal Cancer
  • YERBA SALON 15: Radiotherapy for Hypopharynx Cancer
  • YERBA SALON 15: Cancer of the Hypopharynx
[/tab][tab title=”Sunday“]
  • YERBA SALON 1-2: Tumor Volume as Outcome Predictor in Chemoradiation for Advanced Head & Neck Cancer
  • YERBA SALON 1-2: CI-1040 Inhibits Growth of Papillary Thyroid Carcinoma
  • YERBA SALON 1-2: IRX-2, a Multi-targeted Biologic, Protects T Cells from Tumor-induced Cell Death
  • YERBA SALON 1-2: Does Post-treatment Surveillance Improve survival in Head & Neck cancer Patients?
  • YERBA SALON 1-2: HPV-16 Influence on Oropharyngeal Cancer Treated in a Large Multidisciplinary Setting
  • YERBA SALON 1-2: Involvement of Rho C in Head & Neck Cancer Metastasis
  • YERBA SALON 1-2: Levels of CD44, a Head & Neck Cancer Stem Cell Marker, Correlate with Tumor Aggressiveness
  • YERBA SALON 1-2: Cetuximab Mediated Lysis is regulated by Polymorphic FcγR-IIIa NK Cells
  • YERBA SALON 1-2: DAHANCA 10 – a Randomized Study of Aranesp® as Modifier of Radiotherapy in Patients with Primary HNSCC
  • YERBA SALON 1-2: HPV-16 E6 and E7 Transactivate a Human Endogenous Retroviral Superantigen that is Expressed in HPV+OSCC
  • YERBA SALON 1-2: Phase II Study of Bevacizumab, Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head & Neck
  • YERBA SALON 1-2: CWRU 1301: Phase I Study of the EGFR Tyrosine Kinase Inhibitor Erlotinib (Tarceva) in Combination with Docetaxel & Radiation
  • YERBA SALON 1-2: Detection of Promoter Hypermethylation of Multiple Genes in tumor and Serum Samples of Patients with HNSCC
  • YERBA SALON 1-2: The Effect of Over Expression of the Intrinsic Hypoxia Markers HIF1a, CA-IX and GLUT-1 on local Recurrence in T1/T2 Glottic Laryngeal Carcinoma Treated with Radiation Therapy
  • YERBA SALON 1-2: Noninvasive Detection of HPV & Associated Genetic Alteration in Squamous Head & Neck Cancer
  • YERBA SALON 1-2: Quantitative Methylation Analyses of Resection Margins Predict Local Recurrences and Disease specific survivals in Head & Neck Squamous Cell Carcinomas
  • YERBA SALON 1-2: Engineering an Artificial Salivary Gland
  • YERBA SALON 3-4: Functional Imaging Evaluation of Response to Therapy
  • YERBA SALON 3-4: ASHNR Panel: Post-treatment Imaging and Complications
  • YERBA SALON 3-4: Novel Targeted Therapeutic Approaches to Squamous Cell Carcinoma of the Head & Neck
  • YERBA SALON 3-4: Pitfalls in PET/CT/MR of the Post-treatment Head & Neck Cancer Patients
  • YERBA SALON 3-4: Radiation Therapy Planning Novel PET Tracers
  • YERBA SALON 3-4: HPV16 and Oropharyngeal Cancer
  • YERBA SALON 3-4: FDG-PET for Head & Neck Cancer: Initial Starting
  • YERBA SALON 5-6: Genetic Classification of Head & Neck Cancer
  • YERBA SALON 5-6: Proteomic Profiling to Predict Chemotherapy Response in HNSCC
  • YERBA SALON 5-6: Head & Neck Cancer Virology
  • YERBA SALON 5-6: Oral HPV Infection
  • YERBA SALON 5-6: EBV and NPC: Diagnostic and Therapeutic Opportunities
  • YERBA SALON 5-6: Utilization of Protein Arrays for Head & Neck Cancer Analyses
  • YERBA SALON 5-6: HPV as a Risk Factor for Head & Neck Cancer
  • YERBA SALON 5-6: Expression Array Analyses to Predict HNSCC Behavior
  • YERBA SALON 5-6: Genomics/Proteomics in Head & Neck Cancer
  • YERBA SALON 10-11: Sentinel Node Biopsy in Oral/Oropharyngeal Squamous Cell Cancer
  • YERBA SALON 10-11: Sentinel Lymph Node Biopsy for Squamous Cell Carcinoma of the Oral Cavity
  • YERBA SALON 10-11: TH1/TH2 CD4+ T Helper Responses Against Wild-type Sequence P53 Peptides in HLA-DP5 Patients with Head & Neck Cancer
  • YERBA SALON 10-11: The Important of Immunohistochemistry in Sentinel Lymph node Analysis in Head & Neck Cancer
  • YERBA SALON 10-11: Epigenetic Effect of Gossypol in In-vitro Suppression of Head & Neck Squamous Cell Carcinoma
  • YERBA SALON 10-11: Promoter Hypermethylation and Hypomethylation in Oral Squamous Cell Carcinoma
  • YERBA SALON 10-11: Ligands on Head & Neck Squamous Cell Carcinoma Mediate Low Shear-resistant Binding to Lymphocytes via L-selectin
  • YERBA SALON 10-11: Interleukin 8 is Regulated by Transcription Factor ATF2 in HNSCC
  • YERBA SALON 10-11: Selective Versus Comprehensive Neck Dissection after Chemoradiation Therapy for Advanced Head & Neck Squamous Cell Carcinoma
  • YERBA SALON 10-11: Relative Efficacy of Histopathology, IHC and RT-PCR to detect Occult Metastasis in Sentinel Lymph Nodes
  • YERBA SALON 10-11: How Many Nodes are needed to Stage a Neck?
  • YERBA SALON 10-11: Radiation and Cisplatin require an Immune Mechanism for Curing HPV + Cancer
  • YERBA SALON 10-11: Planned Neck Dissection (PND) after Chemoradiotherapy in Locally Advanced Head & Neck Cancer
  • YERBA SALON 10-11: Incidence of Regional Recurrences after Radiotherapy for Head & Neck Squamous Cell Carcinoma (HNSSC)
  • YERBA SALON 10-11: Global Proteomic Analysis of HNSCC Identifies Prognostic Peptides
  • YERBA SALON 10-11: Proinflammatory Mediators Upregulate Snail in HNSCC
  • YERBA SALON 10-11: Defining an Epigenetic Continuum to Malignancy in Laryngeal Papillomatosis
  • YERBA SALON 10-11: Triggering of TLR4 or TLR9 on Human Head & Neck Squamous Cell Carcinomas (HNSCC) Induces Distinct Biological Effects
  • YERBA SALON 12-13: Minor Salivary Gland Carcinoma of Oropharynx and Oral Cavity
  • YERBA SALON 12-13: 3D Tomosynthesis: Novel “Real-Time” Intraoperative Imaging Technology for Guidance of Skull Base Surgery
  • YERBA SALON 12-13: Does Scar Length Really Matter in thyroid Surgery: a Prospective Randomized Clinical Trial
  • YERBA SALON 12-13: Efficacy of Recurrent Laryngeal monitoring in an Otolaryngology Academic Training Program
  • YERBA SALON 12-13: Elevated Postoperative PTH Levels in Primary Hyperparathyroidism
  • YERBA SALON 12-13: Usefulness of Intraoperative Methylene Blue Infusion in Parathyroidectomy for Secondary Hyperparathyroidism
  • YERBA SALON 12-13: Preoperative Localization of Parathyroid Adenomas Using SPECT-CT Imaging
  • YERBA SALON 12-13: Paratracheal Neck Dissection: Indications, Technique, Surgical Results
  • YERBA SALON 12-13: Comparison of Trends in Incidence and Mortality from thyroid Cancer in the UK and USA
  • YERBA SALON 12-13: Outpatient Thyroidectomy: Experience in over 200 Patients
  • YERBA SALON 12-13: Ultrasound of Cervical Lymph Nodes
  • YERBA SALON 14: Carotenoids: Friend or Foe in Cancer Chemoprevention
  • YERBA SALON 14: Tube Feeding in Head & Neck Cancer Patients Receiving Radiotherapy and Chemotherapy
  • YERBA SALON 14: Complementary Serum Test of Antibodies to EBV EA+EBNA-1: a Possible Alternative for Primary Screening of NPC
  • YERBA SALON 14: Does Neck Dissection after Chemoradiation therapy for Oropharyngeal Carcinoma Affect Swallowing Function?
  • YERBA SALON 14: Influences and Predictors of Long-term Quality of Life in Head & Neck Cancer Survivors
  • YERBA SALON 14: Merck-Serono: Honoraria for Lectures
  • YERBA SALON 14: Auto-fluorescence screening for Oral Pre-malignant and Malignant Lesions
  • YERBA SALON 14: Is EGG Based Videostroboscopic Assessment of To Speech Really Useful?
  • YERBA SALON 14: Sequential Pattern of Plasma EBVDNA Copies in a Cohort of High Risk Non-NPC Patients
  • YERBA SALON 14: Early Results of a Long-term Screening Program for Nasopharyngeal Carcinoma
  • YERBA SALON 14: Swallowing Function Following Radiotherapy or Chemoradiotherapy for Advanced Stage Head & Neck Cancer
  • YERBA SALON 14: Pharyngoesophageal Strictures in Head & Neck Cancer
  • YERBA SALON 14: A Tale of Two Sites: Correlation of HPV Subtypes in SCCHN Patients and Cervix of Appalachian Women in West Virginia
  • YERBA SALON 14: Parenteral vs. Enteral nutrition after Major Neck Surgeries
  • YERBA SALON 14: Cigarette Smoke Regulates Reactive Oxygen Species Metabolism in the Larynx
  • YERBA SALON 14: Smokescreens and Slights of Hand
  • YERBA SALON 14: Genetic Analysis of Sporadic and Familiar Head & Neck Paraganglioma Tumors
  • YERBA SALON 14: Nutrition & Dietetic Led Gastrostomy Pathway of Care for Insertion & Removal contributes to Outcomes
  • YERBA SALON 14: Long-term Results of Provax ActiValve, Solving the Problem of Frequent Canida-and “underpressure”-related Voice Prosthesis Replacements
  • YERBA SALON 15: Assessment of Quality of Life Following Anterior Skull Base Tumor Resection a Prospective Study
  • YERBA SALON 15: Breaking Robustness: A Model for Head & Neck Cancer Progression
  • YERBA SALON 15: The Effect of Autologous Platelet Adhesives on Dermal Fat Graft Resorption Following Reconstruction of a Superficial Parotidectomy
  • YERBA SALON 15: EIF2c2 is Amplified and Over-expressed in HNSCC
  • YERBA SALON 15: Low Level Expression of MicroRNA’s let7-d and miR-205 are Prognostic Markers of Head & Neck Squamous cell Carcinoma
  • YERBA SALON 15: Gene expression Profiles Associated with Metastasis and Survival in Patients will Oral Tongue SCC
  • YERBA SALON 15: Intra-tumoral Lymphatics Correlates with Regional Metastases in the Tongue Cancer
  • YERBA SALON 15: Surgical Technique of “Facial Dismasking Approach” for Craniofacial Lesion
  • YERBA SALON 15: Nomogram for Disease-specific Survival in HNSCC
  • YERBA SALON 15: Genetic Expression Associated with Oral Cancer Identifies a Group of Patients at High-risk of Poor Survival
  • YERBA SALON 15: Microvascular Free Tissue Transfer for Defects of the Scalp and Lateral Temporal Bone
  • YERBA SALON 15: Endoscopic Dural Resection in the Management of Selected Sino-nasal Malignancies: Surgical Technique and Morbidity
  • YERBA SALON 15: Preclinical Development of a Novel Cancer Cell Homing, PKCε Inhibitory Peptide for Head & Neck Cancer
  • YERBA SALON 15: Parathyroid Carcinoma
  • YERBA SALON 15: CT-MIBI Fusion Localization in Directed Parathyroidectomy
  • YERBA SALON 15: Assessing the Impact of Variations in Baseline Parathyroid Hormone Levels on surgical Treatment of Primary Hyperparathyroidism
  • YERBA SALON 15: 634 Directed Parathyroidectomies: Lessons Learned
  • YERBA SALON 15: Ubc9 Expression by HNSCC: Correlation with Clinical Parameters and Proliferation
  • YERBA SALON 15: Navigated Control: Surgical Assistance for Skull Base Surgery
  • YERBA SALON 15: Results of Proton Beam Radiation therapy for Locally Advanced Squamous Cell Carcinoma (SCC) of the Paranasal Sinus and Nasal Cavity
  • YERBA SALON 15: Clinical Outcomes of Sinonasal Cancer Treated with Endoscopic Endonasal Resection
  • YERBA SALON 15: Treatment of Esthesioneuroblastoma with a Completely Endoscopic Endonasal Cranial Base Resection
  • PACIFIC B: Session – LWP02. Cancer Prevention and Premalignancy
  • PACIFIC C: CT/MR for Assessing Treatment Response
  • PACIFIC C: Avoiding Pitfalls in the Post-Treatment Neck
  • PACIFIC E: “Minimally Invasive” Paranasal Sinus-Cranial Base Surgery
  • PACIFIC F: Non-PET-based Techniques for Functional H+N Imaging
  • PACIFIC F: Imaging for Surveillance
  • PACIFIC F: Imaging for surveillance Part II: Case Examples
  • PACIFIC H: PET/CT in Neck Imaging: Practical Considerations
  • PACIFIC H: PET in Head & Neck
  • PACIFIC J: Ultrasound in Head & Neck Cancer Staging: Case Studies
[/tab][tab title=”Monday“]
  • YERBA SALON 1-3: Mandibular Condyle Reconstruction with Fibular Free Tissue Transfer
  • YERBA SALON 1-3: Versatility of the ALT Flap in Head & Neck Reconstruction
  • YERBA SALON 1-3: Perioperative Airway Management in Patients receiving Oral cavity Free flap Reconstruction: Can Tracheotomy be Safely Avoided?
  • YERBA SALON 1-3: Free Posterior Tibial Flap for Head & Neck Reconstruction after Tumor Resection
  • YERBA SALON 1-3: Mandibular Defect Reconstruction with Composite Free Flaps and the Use of the 2.0 mm Unilock system
  • YERBA SALON 1-3: Designing Chimera Flaps in Multiple Vascular systems
  • YERBA SALON 1-3: Screening of Hypopharyngeal Cancer with the Hooded Videoendoscopy and the Narrow Band Imaging for Esophageal Cancer Patients
  • YERBA SALON 1-3: Stereolithographic Biomodeling in Mandibular Reconstruction: a Prospective Trial
  • YERBA SALON 1-3: Supraclavicular Artery Flap for Oncologic Head & Neck Reconstruction
  • YERBA SALON 4-6: Salvage Surgery for Recurrent H&N Cancer
  • YERBA SALON 4-6: Novel Strategies and Principles of Management of Recurrent Cancer of the Head & Neck
  • YERBA SALON 4-6: Assaulting Therapeutic Barriers: Re-irradiation and Chemotherapy in Recurrent SCCHN
  • YERBA SALON 4-6: Local Regional Recurrent Disease
  • YERBA SALON 10-11: Immunostaining Patterns of CD31 and Podoplanin in Previously Untreated Advanced Oral/Oropharyngeal Cancer
  • YERBA SALON 10-11: A Prospective Study of Surgical Margin Status in Oral Squamous Cell Carcinoma – A Preliminary Report
  • YERBA SALON 10-11: Management of the Clinically No Neck in Oral and Oropharyngeal Carcinoma in Scotland
  • YERBA SALON 10-11: Enhancement of Antitumor Activity Using Cetuximab and novel Epidermal Growth Factor Receptor (EGFR) Peptide-specific T Cells
  • YERBA SALON 10-11: Identification of Stem-like Calls in Head & Neck Cancer Cell Lines
  • YERBA SALON 10-11: The Toll-like Receptor 9 Agonist ODN1826 Inhibits Cachexia and Tumor Growth in Tumor-Bearing Mice
  • YERBA SALON 10-11: Synergistic Effect of Resveratrol with Etoposide and Cisplatin in Merkel Cell Carcinoma Cell Lines
  • YERBA SALON 10-11: Salivary Transcriptomes as Potential Early Detection Biomarkers for Oral Cancer
  • YERBA SALON 10-11: Metastases to Level llb in Oral Cavity Cancer: A Systematic Review and Meta-analysis
  • YERBA SALON 10-11: Vaccination with Ad E6/E7 Prevents HPV Related Cancer in Vivo
  • YERBA SALON 10-11: Analysis of Risk Factors Predictive of Local Tumor Control in Oral Cavity Cancer
  • YERBA SALON 10-11: Factor Contributing Need of Tracheostomy and Strategies to Overcome that in Patients Undergoing Oral and Oropharyngeal Cancer surgery
  • YERBA SALON 10-11: Marginal Mandibulectomy for Buccal Sulcus Cancers: 10 Year Institutional Experience
  • YERBA SALON 10-11: Sequential Therapy for Locally Advanced Larynx and Hypopharynx Cancer
  • YERBA SALON 10-11: FGF2-retageted Adenoviral Gene Therapy for MRN Disruption Induces Cisplatin Chemosensitization for Head & Neck Cancer
  • YERBA SALON 12-13: Autofluorescence Imaging and Molecular Markers combined, Provide a Robust Predictive Strategy in Oral Cavity Malingnancy
  • YERBA SALON 12-13: The Role of Imaging Studies for the Detection of Retropharyngeal Lymph Node Metastasis in Head & Neck Cancer
  • YERBA SALON 12-13: Detection of Pulmonary Tumours in Patients with Head & neck Squamous Cell Carcinoma at the time of Original Presentation
  • YERBA SALON 12-13: Is there any Additional Value of SPECT/CT Over Lymphoscintigraphy for Sentinel node Mapping in Oral/Oropharyngeal SCC?
  • YERBA SALON 12-13: Organ Preservation with Concurrent Chemoradiation for Advanced Laryngeal Cancer: Are We Succeeding?
  • YERBA SALON 12-13: RECISTing the Neck: Interobserver Variability in the Use of RECIST Criteria for Neck Tumors
  • YERBA SALON 12-13: PET-CT in the Management of Head & Neck Malignancies
  • YERBA SALON 14-15: An Evaluation of Trends in the Quality of Research in the Subspecialty of Head & Neck Oncology
  • YERBA SALON 14-15: Socioeconomic Status as a Predictor of Survival in Head & Neck Cancer Patients
  • YERBA SALON 14-15: How Representative are Published Studies in Patients with Head & Neck Cancer of the Total Population of Patients?
  • YERBA SALON 14-15: Are We Overestimating the Risk of Second Malignancies in Patients with Head & Neck Cancer?
  • YERBA SALON 14-15: Second Primary Tumours in Laryngeal SCCs are not Associated with Poorer Overall Outcome and Survival
  • YERBA SALON 14-15: Microvascular changes in Oral Mucositis
  • YERBA SALON 14-15: Prospective Multicenter phase III Randomized Study Comparing Oral Pilocarpine vs. Submandibular Salivary gland Transfer Protocol for the Management of XRT Induced Xerostomia
  • YERBA SALON 14-15: Telomerase Activity in Peripheral Whole Blood of Head & Neck Squamous Cell Carcinoma Patients Before and after Surgery
  • YERBA SALON 14-15: Anon-invasive Diagnostic Technique Using Time-resolved Laser-induced Fluorescence Spectroscopy in the Hamster model
  • YERBA SALON 14-15: A 3-D Interactive Pathology Visualization System
  • YERBA SALON 14-15: Oral Cancer Trends Over Three Decades from 1984-2004 in the West Midlands, UK
  • YERBA SALON 14-15: Bioengineered Human Salivary Tissue Constructs for the Treatment of Radiation Induced Xerostomia
  • YERBA SALON 14-15: Trans Oral Robotic Surgery (TORS)
  • PACIFIC A: Early Laryngeal Cancer
  • PACIFIC B: T3N3 Tumor of the Hypopharynx: No Significant Comorbidities
  • PACIFIC B: Induction Chemotherapy and Concomitant Chemoradiotherapy for Locoregionally Advanced Head & Neck Cancer
  • PACIFIC C: Role of Surgery in the Palliative Treatment of Head & Neck Carcinoma
  • PACIFIC E: Practice Guidelines: Cost Control in Head & Neck Cancer
  • PACIFIC E: Organ Preservation in Brazil. Can We Afford It?
  • PACIFIC F: Symptom control for Non-Surgical Treatments
  • PACIFIC H: Progress in Medical Treatment of Incurable Salivary Gland and Thyroid Cancers
  • PACIFIC H: Novel Agents in Thyroid Cancer
  • PACIFIC I: Angiogenesis Inhibition in HNSCC
  • PACIFIC J: Target Therapy. Kinase Inhibition.
[/tab][tab title=”Tuesday“]
  • YERBA SALON 1-3: Biomarkers in Oral Dysplasia: A systematic Review
  • YERBA SALON 1-3: Unilateral Thyroid Lobectomy for Differentiated thyroid Carcinoma
  • YERBA SALON 1-3: Marginal Mandibular Nerve Injury in Neck Dissection and its Impact on Patient Perception of Appearance
  • YERBA SALON 1-3: Comparing Prognostic Outcomes of Tall Cell Variant to Normal Variant Papillary Thyroid Carcinoma: a Meta-analysis
  • YERBA SALON 1-3: Early Experience Using Time – and Swept Source Frequency domain Optical coherence Tomography in Head & Neck Oncology
  • YERBA SALON 1-3: The Influence of Passive vs Suction Drainage on Complications Following Neck Dissection
  • YERBA SALON 1-3: Substernal Goiters and Sternotomy
  • YERBA SALON 1-3: Outcomes of Untreated Papillary Thyroid Cancer
  • YERBA SALON 1-3: Molecular Imaging of Sentinel Lymph Mode Metastases Using Oncolytic Herpes Simplex Virus-mediates Transgene Expression
  • YERBA SALON 1-3: Surgical Management of Well Differentiated Thyroid Carcinoma
  • YERBA SALON 1-3: Colour Flow Doppler and the Anterolateral Thigh Flap: Clinical Utility
  • YERBA SALON 1-3: Risk-adjusted Use of FDG-PET/CT in Radiation Response Assessment for HNSCC
  • YERBA SALON 1-3: Shoulder Morbidity Following Pectoralis Major Flap Reconstruction
  • YERBA SALON 1-3: Chemo-selection as a Strategy for Organ Preservation
  • YERBA SALON 1-3: Geldanamycin Treatment Radiosensitize Head & Neck Carcinoma Cells by Promoting EGFR Degradation
  • YERBA SALON 1-3: ICC 2302: Phase II Study of Combretastatin A4 Phosphate (CA4P, Fosbretabulin) on Advanced Anaplastic Thyroid Carcinoma
  • YERBA SALON 1-3: Complications of total Thyroidectomy in Benign vs Maligant Disease
  • YERBA SALON 1-3: Comparison of Post-operative Complications after Thyroidectomy with and without Central Compartment Dissection
  • YERBA SALON 1-3: Papillary Thyroid Cancer in Children: Management and Patterns of Failure
  • YERBA SALON 4-6: Neuroradiology of Nasopharyngeal Cancer Diagnosis and Patterns of Spread
  • YERBA SALON 4-6: Chemo/IMRT. IMRT-Debates
  • YERBA SALON 4-6: The Radiation Oncologists Cannot Reproducibly Choose What to Treat
  • YERBA SALON 4-6: IMRT, Especially when Combined with Chemo, is too Toxic and Dangerous
  • YERBA SALON 4-6: Conclusions
  • YERBA SALON 4-6: Chemo/IMRT is either too Toxic or too Dangerous… The Cons…
  • YERBA SALON 4-6: Nasopharyngeal Cancer
  • YERBA SALON 4-6: IMRT in the Treatment of Nasopharyngeal Carcinoma (NPC)
  • YERBA SALON 4-6: Nasopharyngeal Cancer
  • YERBA SALON 4-6: Nasopharyngeal Carcinoma: Recurrent Metastatic and biologic Targeted therapy
  • YERBA SALON 10-11: Expression of CD24, EGFR, and MDM2 Predict Disease Specific Survival in Patients with Advanced Laryngeal Cancer
  • YERBA SALON 10-11: Response to Induction Chemotherapy and Chemoradiation is Predicted by Low Expression of BAK and NFkB in Patients with Advanced Laryngeal Cancer
  • YERBA SALON 10-11: Shoulder Morbidity after Surgical and Non-surgical Treatment of the Neck
  • YERBA SALON 10-11: Expression of Hedgehog Signaling Molecules in Merkel Cell Carcinoma
  • YERBA SALON 10-11: The Clinical Significance of Loss of Heterozygosity in Head & Neck Squamous Cell Carsinoma
  • YERBA SALON 10-11: Molecular Staging of Surgically Treated Head & Neck Cancer Patients
  • YERBA SALON 10-11: Improved Outcome with Neck Dissection Following Chemoradiation for N3 Disease
  • YERBA SALON 10-11: Positron Emission Tomography in the Management of Head & Neck Cancer of Unknown Primary
  • YERBA SALON 10-11: Quality of Life after Neck Dissection
  • YERBA SALON 10-11: Diffusion-weighted MRI for Nodal Staging of Locally Advanced Head & Neck Squamous Cell Carcinoma: Impact on Radiotherapy Planning
  • YERBA SALON 10-11: DCE-MRI Perfusion Imaging of HNSCC Nodal Metastasis
  • YERBA SALON 10-11: The Prognostic Significance of Tumour HIF-1a Expression for Outcome Following Radiotherapy in Oropharyngeal Cancer
  • YERBA SALON 10-11: Initial Staging of the Neck in HNSCC: is PET/CT the best?
  • YERBA SALON 10-11: FcγIIIA Polymorphisms and Cetuximab Induced Cytotoxicity in SCCHN
  • YERBA SALON 10-11: The role of PGP9.5 as a Tumor Suppressor Gene in Head & Neck Cancer
  • YERBA SALON 10-11: Ultrasound Guided Aspiration Cytology for the Assessment of the clinical NO Neck; Factors Influencing its Accuracy
  • YERBA SALON 12-13: Low Molecular Weight Heparin Thromboprophylaxis and Bleeding risk in Head & Neck Cancer Microvascular Reconstruction
  • YERBA SALON 12-13: Mandibular Reconstruction with Autologus Freeze-treated Bone after Malignant Tumor Resection
  • YERBA SALON 12-13: Free Jejunum Versus Tubed Flaps for Total Laryngopharyngectomy Defects: Patterns of Use and Outcomes
  • YERBA SALON 12-13: A New Option in Maxillary Reconstruction
  • YERBA SALON 12-13: Microvascular Reconstruction in the Setting of Prior Intra-arterial Chemotherapy with Concomitant Radiation
  • YERBA SALON 12-13: Reconstruction of Maxillary Defects-options and Outcome
  • YERBA SALON 12-13: Bone Impacted Fibula (BIF)
  • YERBA SALON 12-13: Radial Forearm Versus Anterolateral Thigh Free Flaps for Laryngopharyngectomy Defects
  • YERBA SALON 12-13: A Practical Approach to Maxillary Reconstruction Based Upon the Patient’s Desire for Dental Rehabilitation
  • YERBA SALON 12-13: Combinatorial therapy for Healing Cranial Defects Compromised by Preoperative Radiation
  • YERBA SALON 12-13: A Prospective Analysis of Factors Predicting Morbidity in Microvascular Free Flap Reconstruction of the Head & Neck
  • YERBA SALON 12-13: Pectoralis Myofascial Flap During Salvage Laryngectomy Prevents Pharyngocutaneous Fistula
  • YERBA SALON 12-13: The Use of Radial Forearm Free Flap for total Lower Lip Reconstruction
  • YERBA SALON 12-13: The Role of Salvage Surgery in Recurrent Oropharyngeal Squamous Cell Carcinoma
  • YERBA SALON 12-13: Efficacy of Low Molecular Weight Heparin in Preventing Free Flap Failure: A Rat Model
  • YERBA SALON 12-13: The Use of Stress-Shielding Reconstruction Plates in Free Fibula Mandible Reconstruction May be Associated with Increase Rates of Bone Resorption
  • YERBA SALON 14-15: Random Positional Variation Amongst the Skull, Mandible and cervical Spine in Daily Setup for Head & Neck Radiotherapy
  • YERBA SALON 14-15: Laser Vestibulectomy for Supraglottic Carsinomas
  • YERBA SALON 14-15: Laser Surgery of Early Glottic Cancer
  • YERBA SALON 14-15: Predictors of outcome for Advanced Stage Supraglottic Laryngeal cancer
  • YERBA SALON 14-15: Two-Year Longitudinal Study of Swallowing After Chemotherapy-IMRT for Head & Neck Cancer
  • YERBA SALON 14-15: Complications and Findings in Panendoscopy of Chemoradiated Patients
  • YERBA SALON 14-15: Endoscopic C02 Laser Supraglottic Laryngectomy Multicenter Analysis of 144 cases
  • YERBA SALON 14-15: Treatment of Pharyngeal carcinomas by Laser Endoscopic Microsurgery
  • YERBA SALON 14-15: Clinical Impact of Introducing Supracricoid Laryngectomy with CHEP
  • YERBA SALON 14-15: Do Team Member Managing Head & Neck Cancer Have the same or different Views when Predicting Quality of Life?
  • YERBA SALON 14-15: Functional Outcomes and Quality of Life
  • YERBA SALON 14-15: Clinical Predictors of Survival with Functional Larynx Preservation after Multiagent Concurrent Chemotherapy and Radiation
  • YERBA SALON 14-15: Validation of the EORTC Quality of life Instruments in Laryngeal Cancer Patients after Surgery
  • YERBA SALON 14-15: Interstitial PDT in Recurrent Head & Neck Carcinoma
  • YERBA SALON 14-15: Phonosurgical Treatment of Early Glottal Cancer: Innovations Through the Past 15 Years
  • PACIFIC B: Hypoxia Research and clinical Practice
  • PACIFIC B: Secreted & Tissue Markers for Hypoxia & Prognosis in Head & Neck Cancer
  • PACIFIC E: Proton Beam Radiation for Head & Neck Cancer
  • PACIFIC H: Current Strategies for Management of XRT Induced Xerostomia
  • PACIFIC J: Orbital and Periorbital Hemangiomas and Vascular Malformations
[/tab][tab title=”Wednesday“]
  • YERBA SALON 1-3: Prevalence of K-RAS Codon 12 Mutations in Locally Advanced Head & Neck Squamous Cell Carcinoma and Impact on clinical Outcomes
  • YERBA SALON 1-3: RT-PCR for Cytokeratin 20 for Molecular Diagnosis of Lymphatic Metastases in Patients with Head & Neck Cancer
  • YERBA SALON 1-3: Heparanase Induces VEGF-C Levels and Facilitates Tumor Lymphangiogenesis
  • YERBA SALON 1-3: Immunology and Stem Cells – the Dysfunctional Tumor Microenviroment as a Barrier to Successful Therapy
  • YERBA SALON 1-3: SCCHN Can Induce T Cell Senescence as a Novel form of Immune Escape
  • YERBA SALON 1-3: PGE² Production is Enhanced in UV Exposed Keratinocytes: Evidence for the Role of 15-Hydroxyprostaglandin Dehydrogenase
  • YERBA SALON 1-3: Tetrathiomolybdate inhibits Head & Neck cancer Metastasis by Decreasing Tumor Cell Invasion & Promoting Tumor Cell Anoikis
  • YERBA SALON 1-3: Oncolytic Herpes Simplex Virus OncoVEX(GALV/CD) Prodrug Activation Enhances Viral Cytotoxicity in Head & Neck Squamous Cell Carcinoma
  • YERBA SALON 1-3: Cancer Stem Cells in Head & Neck Cancer
  • YERBA SALON 1-3: Lymphocyte Homing Receptor/Tumor Ligand Interactions: a Putative Mechanism for Promoting Immune Tolerance
  • YERBA SALON 1-3: Prediction of Local Recurrence after Radiotherapy for Larynx Carcinoma Using Tissue array Immunohistochemistry
  • YERBA SALON 1-3: Inflammatory and Pattern Recognition Receptors Expressed by Cancer Cells
  • YERBA SALON 1-3: EGFRvIII Induces HNSCC Tumor Cell Migration and Invasion via Activation of STAT3
  • YERBA SALON 4-6: Surgery for Preservation of Swallowing
  • YERBA SALON 4-6: The Role of p53 Mutations in Mouse Models for Oral Cancer
  • YERBA SALON 4-6: Measuring and Quantifying Dysphasia
  • YERBA SALON 4-6: Orthotopic Models of Head & Neck Cancer Including Oral SCCA, Thyroid CA, & Salivary CA
  • YERBA SALON 4-6: Swallowing
  • YERBA SALON 4-6: Swallowing and Quality of Life
  • YERBA SALON 4-6: Panel: Mouse Model for Head & Neck Cancer
  • YERBA SALON 4-6: Dissecting Genetic Alterations and Microenvironment Contributing to HNSCC using Mouse Tumors as model System
  • YERBA SALON 10-11: Gene Expression and Promoter Polymorphisms of DNMT3B in NPCs in Taiwan: A Case-Control Study
  • YERBA SALON 10-11: Early Oral Feeding after Salvage Laryngectomy
  • YERBA SALON 10-11: The Role of Induction Chemotherapy for the Management of Sinonasal Undifferentiated Carcinoma
  • YERBA SALON 10-11: Oropharyngeal SCC. Is there a Role for Primary Surgery?
  • YERBA SALON 10-11: Wide Vertical Hemipharyngolaryngectomy for Laryngopharyngeal Cancer: Revised Surgical Technique & Classification
  • YERBA SALON 10-11: Conservative Management of Iatrogenic Esophageal Perforation in Head & Neck Cancer Patients with Esophageal Stricture
  • YERBA SALON 10-11: Supracricoid Partial Laryngestomy after Radiation Failure
  • YERBA SALON 10-11: Endoscopic Treatment for T1-T3 Supraglottic Cancer: a Multi-institutional Series of 127 Patients
  • YERBA SALON 10-11: Stereotactic Radiosurgery for Head & Neck and Skull Base Cancer
  • YERBA SALON 10-11: PET/CT in Previously Treated Skull Base Malignancies
  • YERBA SALON 10-11: Nasopharyngectomy for Recurrent Nasopharyngeal Carcinoma
  • YERBA SALON 10-11: Speech and Swallowing Following Microsurgical Reconstruction of Soft Palate
  • YERBA SALON 10-11: Salvage Laryngectomy Following Organ Preservation Protocols
  • YERBA SALON 10-11: Fascia-only Free Radial Forearm Flap for Resurfacing the Nasopharynx Following Nasopharyngectomy
  • YERBA SALON 10-11: Endoscopic Transpterygoid Nasopharyngectomy for the Treatment of Nasopharyngeal Carcinoma
  • YERBA SALON 10-11: Changing Treatment Paradigms in the Management of Squamous Cell Carcinoma of the Supraglottic Larynx
  • YERBA SALON 12-13: Squamous Cell carcinoma of Oral Tongue (SCCT) in Young Adults
  • YERBA SALON 12-13: Swallowing Function after Intensity-Modulated and Concomitant Boost Radiation Therapy for Oropharyngeal Carcinoma
  • YERBA SALON 12-13: Assessment of Mouth Self Examination for Early Detection of Oral Cancer in a High-risk Population
  • YERBA SALON 12-13: Prediction of Treatment Complications in Patients with Oropharyngeal Cancer
  • YERBA SALON 12-13: Treatment and Follow-up of Oral Dysplasia
  • YERBA SALON 12-13: Radiotherapy as Single-modality Treatment for Head & Neck Paragangliomas
  • YERBA SALON 12-13: Functional Organ Preservation in T4 Laryngeal/Hypopharyngeal Cancer Treatment with Chemoradiation
  • YERBA SALON 12-13: The Pattern of Failure after Re-irradiation of Recurrent Head & Neck Cancer: Sqamous Cell Cancer (HNSCC)
  • YERBA SALON 12-13: Squamous Cell Carcinoma Regional Metastases Treated with Radiation Therapy: Correlation Between CT and Histology
  • YERBA SALON 12-13: Encouraging Presentation of Oral Cancer in a High Risk Group
  • YERBA SALON 12-13: Utilizing 5-Aminolevulinic Acid and Pulsed Dye Laser for Photodynamic therapy (PDT) of Oral Leukoplakia
  • YERBA SALON 12-13: Lack of Association Between HPV Infection and Oral Tongue Carcinoma in Young and Older Adults
  • YERBA SALON 12-13: A Population-based Analysis of the Association of Oral/Pharyngeal Carcinomas with HPV-Related Anogenital Carcinomas in Men
  • YERBA SALON 12-13: Xerostomia in Patients with Head & Neck Tumors Treated by IMRT: Importance of Absolute Spared Parotid Volume
  • YERBA SALON 12-13: Radical Radiation for Unknown Primary Squamous Cell Cancer Yields high Control but has Major Toxicity Suggesting Need for New Treatment Parading
  • YERBA SALON 12-13: A Food-based Approach to Oral Cancer Chemoprevention
  • YERBA SALON 12-13: Dosimetric Uncertainties in Matched IMRT and Conventional Fields for Head & Neck Cancer Radiotherapy
  • YERBA SALON 14-15: “Dual disruption” Therapy for Head & Neck Cancer: Targeting DNA Repair Pathways to Induce Cancer Cell Death
  • YERBA SALON 14-15: Cisplatin and JSI-124 Induce Synergistic Cell Death in a Cisplatin Resistant Cell Line
  • YERBA SALON 14-15: Peri-tumoral Injections of Purified Tumstatin Delay Tumor Growth & Lymphatic Metastasis in an Orthotopic Oral SCC Model
  • YERBA SALON 14-15: Single-walled Carbon Nanotubes Associated with Paclitaxel Inhibit the Growth of Head & Neck Squamous Cell Tumors
  • YERBA SALON 14-15: Salvage Surgery for Recurrent Nasopharyngeal Carcinoma Using a Partial Maxillectomy Approach
  • YERBA SALON 14-15: Metronomic Administration of a Small Molecule Inhibitor of Bcl-2 Combined with Cisplatin in Xenografted Head & Neck Cancer
  • YERBA SALON 14-15: Sensitization of Head & Neck Cancer Cells to Cisplatin is Potentiated by Genistein
  • YERBA SALON 14-15: Preclinical Evaluation of Sunitinib in Squamous Cell Carcinoma of the Head & Neck
  • YERBA SALON 14-15: Hyaluronan and CD44 Interact with RHO-kinase and PI 3-kinase to Promote Gowth, Migration, Invasion, and Cisplatin Resistance in HNSCC
  • YERBA SALON 14-15: Assessment of EGFR Inhibition by Erlotinib in Tumors as Compared with normal Mucosa in Patients with Oral Cavity Squamous Cell Carcinoma
[/tab][/tabs]

Share:

  • Facebook
  • Twitter
  • LinkedIn

AHNS Meetings

WEBINAR CALENDAR

AHNS Call For Abstracts

News and Announcements

  • AHNS 2023 Meeting – Late Breaking Call For Abstracts – 1 Week Left To Submit Abstracts March 16, 2023
  • Registration for the AHNS 2023 is now open! March 10, 2023
  • What’s New on the AHNS Website March 9, 2023
  • AHNS 2023 Meeting – Late Breaking Call For Abstracts – Submission Site Now Open March 8, 2023
  • Remembering Dr. Giovana R. Thomas March 7, 2023

AHNS on Facebook

AHNS on Facebook

Contact Us

AHNS, 11300 W. Olympic Blvd, Suite 600
Los Angeles, CA 90064
ph: (310) 437-0559 / fx: (310) 437-0585
[email protected]

Search this website

Follow the AHNS

  • Email
  • Facebook
  • Twitter
  • YouTube

Recent Heads Up! Posts

AHNS 2023 Meeting – Late Breaking Call For Abstracts – 1 Week Left To Submit Abstracts

Registration for the AHNS 2023 is now open!

What’s New on the AHNS Website

More News and Announcements

© 2002–2023 American Head and Neck Society · Privacy and Return Policy
· Managed by BSC Management, Inc